Cystoscope Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type (Rigid Cystoscope, Flexible Cystoscope), By Applications (Urology, Gynaecology), By End-User (Hospitals, Ambulatory Surgical Centres), And By Geography - Forecasts From 2021 To 2026

Cystoscope Market is projected to grow at a CAGR of 3.77% between 2025 to 2030.

A cystoscope is a thin, telescope-like tube with a light and tiny camera attached instrument used to perform a cystoscopy, also known as cystourethroscopy that allows a physician to examine and treat the lower urinary tract (urethra, prostate, bladder neck, and bladder). The cystoscope is inserted into the bladder through the urethra for the evaluation, treatment, or diagnosis of the conditions such as Bladder cancer, haematuria, frequent urinary tract infections (UTIs), Urinary blockage, Urinary stones, etc. making cystoscopy procedures one of the most commonly performed procedures in the urology office settings. Major companies have been providing novel and advanced solutions for their customers. For instance, Ambu, one of the largest suppliers of innovative and advanced single-use endoscopes, would be providing solutions for urology, in the coming years. The company had announced that it would launch a novel single-use, sterile, and high-resolution cystoscope in the year 2022. The company had also stated that they would launch a novel and single-use digital flexible ureteroscope in the year 2022. These trends and developments are expected to play a major role in the market growth, during the forecast period.

Rising incidences of urinary tract diseases boost the market.
The growth in the global cystoscope market may be attributed to the rising prevalence of urinary tract diseases globally. As per the data from the National Kidney Foundation, there are approximately 10 million doctor visits for urinary tract infections in the US. Similar rising incidences of other diseases such as prostate cancer, stones, bladder cancer, etc. will also boost the market during the given time frame. As per Cancer Research UK, prostate cancer is the most common cancer in men with around 47,700 new prostate cancer cases in the UK every year. However, complications such as infections, bleeding, and swollen urethra that may arise during cystoscopy procedures might restrain the growth of the market during the forecast period. According to a journal published in the United States National Library of Medicine National Institutes of Health, urinary tract infections are one of the most common infections, with an average lifetime incidence of 50-60% in most adult women. Urinary tract infections are some of the most common infections in the United States. The prevalence in women over 65 years is around 20%, compared with around 11% of the overall population. Moreover, there are around 258,000 cases of pyelonephritis in the United States, per year, with a higher and bigger frequency among females. In women, who are aged between 18-49 years, the total approximate incidence of pyelonephritis is around 28/10,000. These trends are expected to accelerate the demand for novel cystoscope devices and applications, in the coming years.

The Asia Pacific has a major share.

The market is expected to surge in the region due to the rising cases of urinary infections and prostate cancer. In India, according to the Indian Council of Medical Research, the incidence rate of prostate cancer in the country had been around 9-10/per 100,000 population, which is comparatively higher as compared to countries in Asia and Africa. In China, according to the National Cancer Registration Institute, prostate cancer has been the most common tumor in the male urinary system since the year 2008. These trends are expected to accelerate the demand for novel and advanced cystoscope products and systems.

Latest Developments.

• In May 2021, UroViu Corporation, one of the major developers of a suite of self-contained, portable, and versatile single-use cystoscopy solutions, had announced that they had received clearance from the United States Food and Drug Administration to market and launch its third device, known as Uro-G. The novel product had been a single-use cystoscope with a detectable tip that allows physicians to perform diagnostic and interventional urologic procedures in their clinics, at any time, and in any room. This development is expected to have a positive impact on the market, in the coming years.
• In May 2021, KARL STORZ Endoscopy America Inc., one of the key players in the market, announced the launch of its novel PDD Blue Light Flexible Video Cystoscopy System for improved detection of non-muscle invasive bladder cancer. The company had stated that the novel indications would surge the treatment of innovative therapy, across the United States.
• In April 2021, Ambu Inc., one of the key players in the market, announced that it had received Health Canada clearance for the aScope 4 Crysto, the firm’s major advanced and innovative flexible cystoscope platform for urology. The novel product would allow urologists in Canada immediate access to a single-use cystoscope option for managing, treating, and diagnosing lower urinary disorders, such as bladder cancer, incontinence, and hematuria. 

 Segmentation:

• By Type
  • Rigid Cystoscope
  • Flexible Cystoscope
• By Applications
  • Urology
  • Gynecology
• By End-User
  • Hospitals
  • Ambulatory Surgical Centers
• By Geography
  • North America
    • USA
    • Canadá
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Others
  • Middle East and Africa
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Thailand
    • Taiwan
    • Indonesia
    • Others

Stryker

PENTAX Medical

Olympus Medical Corporation

Richard Wolf GmbH

Karl Storz

NeoScope Inc.

Coloplast Group

Cogentix Medical

Henke-Sass Wolf

Advanced Health Care Resources